- Home
- VERU vs EPIX Comparison
VERU vs EPIX Comparison
Compare VERU & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- EPIX
- Stock Information
- Founded
- VERU 1971
- EPIX 2009
- Country
- VERU United States
- EPIX Canada
- Employees
- VERU N/A
- EPIX N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- EPIX Health Care
- Exchange
- VERU Nasdaq
- EPIX Nasdaq
- Market Cap
- VERU 76.9M
- EPIX 65.3M
- IPO Year
- VERU 1990
- EPIX N/A
- Fundamental
- Price
- VERU $0.50
- EPIX $1.69
- Analyst Decision
- VERU Strong Buy
- EPIX Hold
- Analyst Count
- VERU 2
- EPIX 3
- Target Price
- VERU $4.00
- EPIX $2.00
- AVG Volume (30 Days)
- VERU 856.5K
- EPIX 153.9K
- Earning Date
- VERU 05-08-2025
- EPIX 05-08-2025
- Dividend Yield
- VERU N/A
- EPIX N/A
- EPS Growth
- VERU N/A
- EPIX N/A
- EPS
- VERU N/A
- EPIX N/A
- Revenue
- VERU $16,886,419.00
- EPIX N/A
- Revenue This Year
- VERU N/A
- EPIX N/A
- Revenue Next Year
- VERU N/A
- EPIX N/A
- P/E Ratio
- VERU N/A
- EPIX N/A
- Revenue Growth
- VERU 134.43
- EPIX N/A
- 52 Week Low
- VERU $0.45
- EPIX $1.40
- 52 Week High
- VERU $1.42
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- VERU 44.61
- EPIX 49.60
- Support Level
- VERU $0.48
- EPIX $1.63
- Resistance Level
- VERU $0.56
- EPIX $1.79
- Average True Range (ATR)
- VERU 0.02
- EPIX 0.05
- MACD
- VERU -0.00
- EPIX -0.01
- Stochastic Oscillator
- VERU 30.83
- EPIX 37.50
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.